Thiogenesis Therapeutics Corp

As of June 30, 2026, Thiogenesis Therapeutics Corp. carries a market capitalization of 28.86M, placing it among publicly traded companies globally. Its enterprise value stands at 23.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Thiogenesis Therapeutics Corp.'s next confirmed earnings release is scheduled for November 24, 2026.

As of June 30, 2026, Thiogenesis Therapeutics Corp. has 69.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Thiogenesis Therapeutics Corp. maintains a current ratio of 10.81, meaning it holds 10.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Thiogenesis Therapeutics Corp. posted a negative return on equity (ROE) of -181.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -139.41, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Thiogenesis Therapeutics Corp.'s stock has declined approximately 28.68% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Thiogenesis Therapeutics Corp. generated - - in revenue and converted that into -4.59M in net income, yielding earnings per share of -0.09. EBITDA reached -4.60M, while operating income came in at -4.60M.

These figures are as of June 30, 2026. Total book value stands at 4.74M, with working capital of 4.74M providing operational flexibility.

Thiogenesis Therapeutics Corp. produced -4.74M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -21.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Thiogenesis Therapeutics Corp. has an Altman Z-Score of 29.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.